Where does Mitsubishi Tanabe Pharma Corporation rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Mitsubishi Tanabe Pharma Corporation ranks #3,781 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Mitsubishi Tanabe Pharma Corporation hold?

Mitsubishi Tanabe Pharma Corporation holds 96 US utility patents granted between 2015 and 2025, spanning 17 technology areas.

What is Mitsubishi Tanabe Pharma Corporation's Innovation Score?

Mitsubishi Tanabe Pharma Corporation has an Innovation Score of 49.9 out of 100 (top 14% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Mitsubishi Tanabe Pharma Corporation's patent grant rate increasing or decreasing?

Mitsubishi Tanabe Pharma Corporation's recent grant velocity is -35% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Mitsubishi Tanabe Pharma Corporation's patents?

Mitsubishi Tanabe Pharma Corporation's patents average 16.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Mitsubishi Tanabe Pharma Corporation patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Mitsubishi Tanabe Pharma Corporation

Q: What technology areas does Mitsubishi Tanabe Pharma Corporation focus on?

Mitsubishi Tanabe Pharma Corporation's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 84 patents. Grants appear in 17 CPC subclasses total.

USPTO PatentsView assignee record - 96 granted patents across 17 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Mitsubishi ranks #3,781 of 49,997 tracked US assignees by granted-patent volume, with 96 patents across 17 technology areas.

#3,781
of 49,997 US assignees by volume: Top 14%
by Innovation Score (49.9/100): 16.1
avg claims per patent: -35%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R3781 · Foreign Corporation #3,781 · 96 grants

GRANTS-SMALL · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-DOWN · BOOK-FULL

GRANTS-SMALL 96 grants
TOP-DECILE #3,781/49,997
PHOTO-FINISH John Bean
CPC-FOCUS A61P · 17 areas
INNOV-PAR 49.9/100
CLAIMS-RICH 16.1 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DOWN -35% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: John Bean Technologies Corporation (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Mitsubishi Tanabe… · this assignee

50
Universitat DE… · near

50
Connectify · near

50
Fellowes · near

50
Galderma Holding · near

50
3D Lighting… · lowest

7

What this shows Mitsubishi's Innovation Score is 49.9/100 (top 14% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Mitsubishi's grants concentrate

Mitsubishi Tanabe Pharma Corporation is a focused PatentsView assignee: 17 CPC subclasses with 87.5% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2015 (15 grants) versus a trough of 3 in 2020. By volume, Mitsubishi sits between John Bean Technologies Corporation and Suncoke Technology AND Development LLC.

Mitsubishi's three-year grant acceleration

Mitsubishi Tanabe Pharma Corporation shows 25 grants in 2022–2024 against only 17 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

John Bean

96
Karma Automotive

96
Knoll

96
Lite-on Opto Tech…

96
Rogers

96
Rosemount Tank Ra…

96
Shenzhen SNC Opto

96
Suncoke Technolog…

96
Mitsubishi Tanabe… ◀

96

What this shows Mitsubishi holds 96 patents at rank #3,781, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Mitsubishi

By rank, the assignees closest to #3,781 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Mitsubishi's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Mitsubishi, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (50 here).

Universitat DE Barcelona 50 Galderma Holding SA 50 Fellowes, Inc. 50 Connectify, Inc. 50

Similar claim depth

Nearest assignees by average claims per patent (16.1 here).

Trinity Bay Equipment Holdings, LLC 16.1 avg Fina Technology, Inc. 16.1 avg Shanghai Avic Optoelectronics Co., Ltd. 16.1 avg Wits Co., Ltd. 16.1 avg

Mitsubishi's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

50 Top 14% higher than 86% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Mitsubishi Tanabe Pharma Corporation patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	15	15.6%
2016	8	8.3%
2017	15	15.6%
2018	9	9.4%
2019	7	7.3%
2020	3	3.1%
2021	7	7.3%
2022	8	8.3%
2023	9	9.4%
2024	8	8.3%
2025partial year	7	7.3%

Which technologies does Mitsubishi Tanabe Pharma Corporation patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 84

C07D - Heterocyclic Compounds 57

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 53

C07K - Peptides 13

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 10

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 8

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 6

C07C - Acyclic OR Carbocyclic Compounds 5

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 4

Y02A - Technologies FOR Adaptation TO Climate Change 4

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 3

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 3

C12Y - Enzymes 2

A61B - DIAGNOSIS; SURGERY; Identification 1

A61J - Containers Specially Adapted FOR Medical OR Pharmaceutical PURPOSES; Devices OR Methods Specially Adapted FOR Bringing Pharmaceutical Products Into Particular Physical OR Administering FORMS; Devices FOR Administering Food OR Medicines ORALLY; Baby COMFORTERS; Devices FOR Receiving Spittle 1

Top 15 of 17 technology areas

Where it ranks

Overall rank by patents

#3,781

of 49,997 tracked assignees

Innovation Score

49.9 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Mitsubishi Tanabe Pharma Corporation's patent record in context - here's where to go next.

Mitsubishi Tanabe Pharma Corporation's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 87.5% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #3,781 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Mitsubishi Tanabe Pharma Corporation against John Bean Technologies Corporation, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 49.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.